First Trust NYSE Arca Biotechnology Index Fund news

Strong year-to-date (29.36%) and one-year (55.34%) performance, Zacks ETF Rank of 2 (Buy), reasonable expense ratio of 0.55%, and recommended as a great option for investors seeking biotech exposure.

FBT shows strong 1-year performance (51.6%) but carries significantly higher expense ratio (0.55%), concentrated portfolio risk with only 30 holdings, and higher volatility (max drawdown of 29.9%). Suitable only for risk-tolerant investors with specific biotech conviction.

Higher 1-year returns (51.60% vs 18.30%), concentrated equal-weight approach across 30 biotech companies with potential for outsized gains from breakthrough drugs. However, higher expense ratio (0.55%) and significantly larger maximum drawdown (29.90%) indicate higher risk.

FBT demonstrated superior long-term performance with 53.2% one-year returns and 168% ten-year total returns (10.4% CAGR), outperforming IBB significantly. The concentrated 30-stock strategy with no position exceeding 6% provides a well-diversified approach within its structure, though it carries higher concentration risk than broader alternatives.

Offers slightly lower expense ratio (0.55% vs 0.57%), stronger 10-year performance, and broader biotech exposure with 56% in small-caps. However, higher volatility (beta 0.65), larger maximum drawdown, and no dividend income make it less attractive than PJP for most investors.

Presented as a viable alternative for investors seeking concentrated biotech exposure, but disadvantaged by higher expense ratio (0.55%), lower 1-year return (35.90%), and no dividend income compared to XPH.

Offers diversified exposure to 30 biotech companies with $2.92 billion in net assets; rallied 29.8% year-to-date with Zacks ETF Rank #2 (Buy).